HT
HTFL.US Heartflow, Inc. Common Stock
- Market cap
- USD 4.26B
- P/E
- 72.3x
- P/B
- 15.07x
- ROE
- -25.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is HTFL.US undervalued?
Graham numberThe Graham number of Heartflow, Inc. Common Stock cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Heartflow, Inc. Common Stock fundamental analysis
No fundamental analysis for Heartflow, Inc. Common Stock yet.
Heartflow, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Heartflow, Inc. Common Stock
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company provides Heartflow RoadMap Analysis that off…
Full company profileHeartflow, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Heartflow, Inc. Common Stock annual financial statements
| Item | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 87.2M | 126M | 176M | 253M |
| Gross Profit | 58.1M | 94.4M | 135M | 208M |
| Operating Income | -72.9M | -61.2M | -64.1M | -71.7M |
| EBITDA | -62.8M | -65.5M | -93.1M | -66.5M |
| Net Income | -95.7M | -96.4M | -117M | -72.8M |
| EPS | -1.50 | -1.53 | -1.37 | -0.83 |
| Balance Sheet | ||||
| Total Assets | 185M | 119M | 359M | 355M |
| Total Liabilities | 963M | 978M | 58.8M | 72.8M |
| Shareholders' Equity | -778M | -859M | 301M | 283M |
| Cash & Short-term Investments | 123M | 51.4M | 177M | 168M |
| Total Debt | 161M | 160M | 22.1M | 25.9M |
| Cash Flow | ||||
| Operating Cash Flow | -76.4M | -69.0M | -54.0M | -51.1M |
| Capital Expenditure | 6.11M | 4.36M | 5.03M | 6.95M |
| Free Cash Flow | -82.5M | -73.4M | -59.0M | -58.1M |
| Ratios | ||||
| ROE | - | - | -38.8% | -25.8% |
| ROA | -51.7% | -81.2% | -32.5% | -20.5% |
| Net Profit Margin | -109.7% | -76.6% | -66.3% | -28.8% |
| Debt to Equity | - | - | 0.07x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Heartflow, Inc. Common Stock dividends
Heartflow, Inc. Common Stock has not paid dividends in the last 3 fiscal years.
Who owns Heartflow, Inc. Common Stock
- Insiders 5.70%
- Institutions 94.30%
- Public & others 0.00%
- Shares outstanding 87.9M
- Free float 68.0M
Top funds holding HTFL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Health Care Inv | 3.20M | 3.64% | -44.83% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.48M | 2.82% | +0.30% | Sep 2026 |
| iShares Russell 2000 ETF | 1.95M | 2.21% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 1.76M | 2.01% | -1.21% | Sep 2026 |
| Invesco Discovery A | 1.40M | 1.60% | +10.04% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 1.15M | 1.30% | +1.08% | Sep 2026 |
| Franklin DynaTech Fund A | 1.00M | 1.14% | 0.00% | Sep 2026 |
| Fidelity Select Health Care | 950K | 1.08% | -9.52% | Aug 2026 |
| Fidelity Small Cap Index | 880K | 1.00% | +0.15% | Aug 2026 |
| Baron Discovery Institutional | 857K | 0.98% | -30.43% | Sep 2026 |
| Fidelity Select Medical Tech and Devcs | 800K | 0.91% | -4.76% | Sep 2026 |
| AB Small Cap Growth A | 798K | 0.91% | -6.03% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 720K | 0.82% | -0.38% | Oct 2026 |
| Janus Henderson Venture D | 610K | 0.69% | 0.00% | Sep 2026 |
| Eventide Healthcare & Life Sciences I | 595K | 0.68% | -16.71% | Jun 2026 |
| Janus Henderson Glb Life Scn I2 USD | 572K | 0.65% | -3.47% | Aug 2026 |
| Baron Opportunity Retail | 530K | 0.60% | -12.79% | Sep 2026 |
| BNP Paribas US Small Cap ClassicC | 519K | 0.59% | -0.76% | Sep 2026 |
| Janus Henderson Global Life Sciences D | 514K | 0.58% | -17.38% | Sep 2026 |
| Fidelity Growth Company Fund | 501K | 0.57% | 0.00% | Aug 2026 |
Top institutions holding HTFL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8.45M | 9.61% | -19.14% | Jun 2026 |
| Wellington Management Company LLP | 7.86M | 8.95% | -34.37% | Jun 2026 |
| BlackRock Inc | 5.20M | 5.91% | +255.38% | Jun 2026 |
| FMR Inc | 4.82M | 5.49% | -10.69% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.58M | 4.08% | +75.20% | Jun 2026 |
| BAMCO Inc | 3.23M | 3.67% | -15.74% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.75M | 3.13% | +45.40% | Jun 2026 |
| Jupiter Topco LLC | 2.42M | 2.75% | 0.00% | Jun 2026 |
| Amvescap Plc. | 2.30M | 2.62% | +20.16% | Jun 2026 |
| AllianceBernstein L.P. | 1.92M | 2.19% | +57.17% | Jun 2026 |
| Point72 Asset Management, L.P. | 1.72M | 1.96% | +219.73% | Jun 2026 |
| Summit Partners Public Asset Management, LLC | 1.69M | 1.93% | +89.96% | Jun 2026 |
| State Street Corp | 1.47M | 1.67% | +225.36% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 1.47M | 1.67% | +3.59% | Jun 2026 |
| Geode Capital Management, LLC | 1.36M | 1.55% | +151.15% | Jun 2026 |
| Nuveen, LLC | 1.35M | 1.54% | +5,722.83% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.05M | 1.20% | +23.82% | Jun 2026 |
| Renaissance Technologies Corp | 994K | 1.13% | +159.71% | Sep 2026 |
| UBS Group AG | 976K | 1.11% | +127.35% | Jun 2026 |
| BNP Paribas Investment Partners SA | 931K | 1.06% | 0.00% | Jun 2026 |
Heartflow, Inc. Common Stock company profile
- Company name
- Heartflow, Inc. Common Stock
- Ticker
- HTFL.US
- Exchange
- USA Stocks
- Listed since
- Aug 8, 2025
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 843
- Fiscal year end
- December
- Address
- 135 Main Street, San Francisco, CA, United States, 94105
- Phone
- 650 241 1221
- Website
- heartflow.com
About Heartflow, Inc. Common Stock
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies. Its platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. HeartFlow, Inc. was formerly known as Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009. The company was incorporated in 2007 and is headquartered in San Francisco, California.
Heartflow, Inc. Common Stock management
10- Mr. John C.M. FarquharPresident, CEO & Director · born 1973
- Mr. Vikram Verghese C.F.A.Chief Financial Officer · born 1985
- Dr. Campbell D.K. Rogers FACC, M.D.Chief Medical Officer & Executive VP · born 1961
- Dr. John Henry Stevens M.D.Co-Founder · born 1961
- Ms. Kathleen CareySenior Vice President of Operations
- Mhairi L. JonesChief Accounting Officer
- Mr. Justin CambraChief Technology Officer
- Mr. Nicholas S. LaudicoVice President of Investor Relations
- Ms. Angela Ahmad J.D.Chief Legal & Compliance Officer
- Mr. Shivanth BhaskaranChief Commercial Operations & Customer Success Officer